Agenus (AGEN) Stock Price

Agenus Price

NASDAQ·CLOSED
7.97USD-0.10 (-1.25 %)
Market closed

Revenue has compounded at 30.8% per year over the past 19 years to 114.20 M USD. Agenus's net margin stands at 0.1%, up from -8.1% several years earlier. Analysts set a median price target of 8.16 USD, implying 2.4% above the current price. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 188% above its 52-week low.

Agenus stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Agenus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Agenus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Agenus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Agenus Stock Price History
DateAgenus Price
8/5/20267.97 USD
8/4/20268.07 USD
8/3/20267.82 USD
7/31/20267.50 USD
7/30/20267.91 USD
7/29/20266.60 USD
7/27/20266.03 USD
7/23/20266.19 USD
7/22/20265.53 USD
7/21/20265.58 USD
7/20/20264.97 USD
7/17/20265.01 USD
7/16/20265.00 USD
7/15/20265.01 USD
7/14/20265.08 USD
7/13/20266.75 USD
7/10/20263.35 USD
7/9/20263.24 USD
7/8/20263.29 USD
7/7/20263.50 USD
7/6/20263.46 USD
7/2/20263.49 USD
7/1/20263.41 USD
6/30/20263.06 USD
6/29/20263.15 USD
6/26/20263.03 USD
6/25/20262.88 USD
6/24/20262.92 USD
6/23/20263.07 USD
6/22/20263.03 USD
6/18/20263.00 USD
6/17/20262.96 USD
6/16/20262.98 USD
6/15/20263.25 USD
6/12/20263.30 USD
6/11/20263.39 USD
6/10/20263.07 USD
6/9/20263.11 USD
6/8/20263.14 USD
6/5/20263.23 USD
6/4/20263.40 USD
6/3/20263.22 USD
6/2/20263.38 USD
6/1/20263.48 USD
5/29/20263.50 USD
5/28/20263.40 USD
5/27/20263.41 USD
5/26/20263.32 USD
5/22/20263.11 USD
5/21/20263.16 USD
5/20/20263.15 USD
5/19/20263.09 USD
5/18/20263.16 USD
5/15/20263.58 USD
5/14/20263.58 USD
5/13/20263.47 USD
5/12/20263.44 USD
5/11/20263.26 USD
5/8/20263.82 USD
5/7/20263.75 USD
5/6/20263.89 USD
5/5/20264.17 USD
5/4/20264.02 USD
5/1/20263.84 USD
4/30/20263.91 USD
4/29/20263.84 USD
4/28/20263.89 USD
4/27/20264.09 USD
4/24/20263.90 USD
4/23/20263.84 USD
4/22/20263.94 USD
4/21/20263.91 USD
4/20/20264.42 USD
4/17/20264.79 USD
4/16/20264.64 USD
4/15/20264.83 USD
4/14/20264.72 USD
4/13/20264.15 USD
4/10/20263.96 USD
4/9/20264.45 USD
4/8/20264.20 USD
4/7/20264.06 USD
4/6/20263.77 USD
4/2/20263.33 USD
4/1/20263.40 USD
3/31/20263.34 USD
3/30/20263.24 USD
3/27/20263.39 USD
3/26/20263.44 USD
3/25/20263.56 USD
3/24/20263.56 USD
3/23/20263.69 USD
3/20/20263.71 USD
3/19/20263.81 USD
3/18/20263.76 USD
3/17/20263.99 USD
3/16/20263.29 USD
3/13/20263.10 USD
3/12/20262.98 USD
3/11/20263.31 USD
3/10/20263.37 USD
3/9/20263.15 USD
3/6/20262.96 USD
3/5/20262.92 USD
3/4/20263.20 USD
3/3/20263.18 USD
3/2/20263.34 USD
2/27/20263.33 USD
2/26/20263.36 USD
2/25/20263.23 USD
2/24/20263.22 USD
2/23/20263.07 USD
2/20/20263.06 USD
2/19/20263.21 USD
2/18/20263.08 USD
2/17/20263.05 USD
2/13/20262.92 USD
2/12/20262.85 USD
2/11/20262.98 USD
2/10/20263.07 USD
2/9/20262.98 USD
2/6/20262.94 USD
2/5/20262.77 USD
2/4/20262.89 USD
2/3/20262.90 USD
2/2/20262.86 USD
1/30/20262.84 USD
1/29/20262.99 USD
1/28/20263.11 USD
1/27/20263.19 USD
1/26/20263.02 USD
1/23/20263.24 USD
1/22/20263.38 USD
1/21/20263.40 USD
1/20/20263.37 USD
1/16/20263.34 USD
1/15/20263.68 USD
1/14/20264.68 USD
1/13/20264.61 USD
1/12/20264.25 USD
1/9/20263.91 USD
1/8/20263.75 USD
1/7/20263.70 USD
1/6/20263.47 USD
1/5/20263.22 USD
1/2/20263.23 USD
12/31/20253.14 USD
12/30/20253.12 USD
12/29/20253.19 USD
12/26/20253.31 USD
12/24/20253.35 USD
12/23/20253.31 USD
12/22/20253.51 USD
12/19/20253.44 USD
12/18/20253.51 USD
12/17/20253.59 USD
12/16/20253.72 USD
12/15/20253.71 USD
12/12/20253.79 USD
12/11/20254.08 USD
12/10/20254.09 USD
12/9/20253.92 USD
12/8/20254.03 USD
12/5/20253.93 USD
12/4/20254.06 USD
12/3/20254.17 USD
12/2/20254.17 USD
12/1/20254.32 USD
11/28/20254.56 USD
11/26/20254.55 USD
11/25/20254.38 USD
11/24/20254.29 USD
11/21/20254.22 USD
11/20/20254.29 USD
11/19/20254.20 USD
11/18/20254.23 USD
11/17/20254.32 USD
11/14/20254.34 USD
11/13/20254.33 USD
11/12/20254.43 USD
11/11/20254.27 USD
11/10/20254.21 USD
11/7/20253.98 USD
11/6/20253.84 USD
11/5/20253.69 USD
11/4/20253.73 USD
11/3/20253.97 USD
10/31/20253.97 USD
10/30/20253.81 USD
10/29/20253.85 USD
10/28/20254.04 USD
10/27/20254.15 USD
10/24/20254.14 USD
10/23/20254.18 USD
10/22/20254.05 USD
10/21/20254.29 USD
10/20/20254.42 USD
10/17/20253.88 USD
10/16/20253.99 USD
10/15/20253.98 USD
10/14/20253.97 USD
10/13/20254.05 USD
10/10/20253.97 USD
10/9/20254.25 USD
10/8/20254.17 USD
10/7/20254.25 USD
10/6/20254.15 USD
10/3/20254.14 USD
10/2/20253.94 USD
10/1/20253.90 USD
9/30/20253.85 USD
9/29/20253.98 USD
9/26/20253.95 USD
9/25/20253.90 USD
9/24/20254.27 USD
9/23/20254.44 USD
9/22/20254.60 USD
9/19/20254.38 USD
9/18/20254.55 USD
9/17/20254.55 USD
9/16/20254.47 USD
9/15/20254.45 USD
9/12/20254.48 USD
9/11/20254.74 USD
9/10/20254.83 USD
9/9/20255.07 USD
9/8/20254.26 USD
9/5/20254.33 USD
9/4/20254.29 USD
9/3/20254.26 USD
9/2/20254.16 USD
8/29/20254.18 USD
8/28/20254.25 USD
8/27/20254.54 USD
8/26/20254.63 USD
8/25/20254.39 USD
8/22/20254.52 USD
8/21/20254.57 USD
8/20/20254.51 USD
8/19/20254.53 USD
8/18/20254.53 USD
8/15/20254.63 USD
8/14/20254.55 USD
8/13/20254.54 USD
8/12/20254.81 USD
8/11/20254.27 USD
8/8/20254.80 USD
8/7/20254.76 USD
8/6/20254.76 USD
Access this data via the Eulerpool API

Agenus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
156.31 M USD
-186.37 M USD
-245.76 M USD
Jan 1, 2024
103.46 M USD
-114.65 M USD
-227.21 M USD
Jan 1, 2025
114.20 M USD
52.19 M USD
115,000.00 USD
Jan 1, 2026 (e)
136.40 M USD
-65.96 M USD
14.28 M USD
Jan 1, 2027 (e)
137.90 M USD
-66.68 M USD
-3.44 M USD
Jan 1, 2028 (e)
128.00 M USD
-61.90 M USD
-9.23 M USD
Jan 1, 2029 (e)
139.30 M USD
-67.36 M USD
-10.95 M USD
Jan 1, 2030 (e)
238.40 M USD
-115.28 M USD
-5.58 M USD

Agenus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 10:25 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
24.0022.0042.0036.00150.0088.00295.0098.00156.00103.00114.00136.00137.00128.00139.00238.00
300.00-8.3390.91-14.29316.67-41.33235.23-66.7859.18-33.9710.6819.300.74-6.578.5971.22
-187.50-327.27-173.81-241.67-12.00-63.6438.31-101.02-51.92-50.4928.9528.9528.9528.9528.9528.95
-45.00-72.00-73.00-87.00-18.00-56.00113.00-99.00-81.00-52.0033.0039.3739.6637.0540.2468.89
-80.00-109.00-101.00-136.00-70.00-121.0025.00-168.00-186.00-114.0052.00-65.00-66.00-61.00-67.00-115.00
-333.33-495.45-240.48-377.78-46.67-137.508.47-171.43-119.23-110.6845.61-47.79-48.18-47.66-48.20-48.32
-87.00-126.00-120.00-159.00-107.00-180.00-23.00-220.00-245.00-227.0014.00-3.00-9.00-10.00-5.00
107.1444.83-4.7632.50-32.7068.22-87.22856.5211.36-7.35-121.43200.0011.11-50.00
4.254.375.057.437.2510.0212.3414.8219.7222.5135.3235.3235.3235.3235.3235.32
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Agenus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Agenus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Agenus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Agenus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Agenus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Agenus stock margins

The Agenus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agenus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agenus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
38.42 %
8.71 %
-8.09 %
Jan 1, 2022
-101.24 %
-172.20 %
-224.51 %
Jan 1, 2023
-52.05 %
-119.23 %
-157.22 %
Jan 1, 2024
-50.79 %
-110.81 %
-219.61 %
Jan 1, 2025
29.63 %
45.70 %
0.10 %
Jan 1, 2026 (e)
29.63 %
-48.36 %
10.47 %
Jan 1, 2027 (e)
29.63 %
-48.36 %
-2.49 %
Jan 1, 2028 (e)
29.63 %
-48.36 %
-7.21 %

Agenus Stock Revenue, EBIT, Earnings per Share

The Agenus earnings per share therefore indicates how much revenue Agenus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
23.97 USD
2.09 USD
-1.94 USD
Jan 1, 2022
6.61 USD
-11.39 USD
-14.85 USD
Jan 1, 2023
7.93 USD
-9.45 USD
-12.46 USD
Jan 1, 2024
4.60 USD
-5.09 USD
-10.10 USD
Jan 1, 2025
3.23 USD
1.48 USD
0.00 USD
Jan 1, 2026 (e)
6.35 USD
-1.87 USD
0.67 USD
Jan 1, 2027 (e)
6.42 USD
-1.89 USD
-0.16 USD
Jan 1, 2028 (e)
5.96 USD
-1.75 USD
-0.43 USD

Agenus business model & stock analysis

Agenus Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Agenus Employees
Details
Date
Agenus Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Agenus Segments

Agenus Revenue by Segment (1/4)

  • 3 Years

  • 5 Years

  • Max

Non Cash Revenue Related To Sale Of Future Royalties
Non-Cash Royalty Revenue Related to the Sale of Future Royalties
Non cash royalty revenue related to the sale of future royalties
Non-Cash Royalty Revenue Related to the Sale of Future Royalties and Milestones
Non cash royalty revenue related to the sale of future royalties and milestone
Royalty Sales Milestone
Revenue member
Pre Commercial Product Revenue
Service Revenue
Other Revenues
Research and Development Revenue
Details
Date
Non Cash Revenue Related To Sale Of Future Royalties
Non-Cash Royalty Revenue Related to the Sale of Future Royalties
Non cash royalty revenue related to the sale of future royalties
Non-Cash Royalty Revenue Related to the Sale of Future Royalties and Milestones
Non cash royalty revenue related to the sale of future royalties and milestone
Royalty Sales Milestone
Revenue member
Pre Commercial Product Revenue
Service Revenue
Other Revenues
Research and Development Revenue
Jan 1, 2018
0.00 USD
0.00 USD
17.31 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
19.47 M USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
30.42 M USD
15.10 M USD
0.00 USD
0.00 USD
0.00 USD
4.68 M USD
99.85 M USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
47.55 M USD
0.00 USD
4.62 M USD
0.00 USD
0.00 USD
91,000.00 USD
98.40 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
44.36 M USD
0.00 USD
6.70 M USD
0.00 USD
0.00 USD
184,000.00 USD
120.70 M USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
45.29 M USD
0.00 USD
25.30 M USD
0.00 USD
0.00 USD
171,000.00 USD
0.00 USD
130.30 M USD
Jan 1, 2024
0.00 USD
100.98 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.00 M USD
0.00 USD
0.00 USD
Jan 1, 2025
108.59 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
4.24 M USD
1.04 M USD
0.00 USD
0.00 USD

Agenus Revenue by Segment (2/4)

  • 3 Years

  • 5 Years

  • Max

License and Collaboration Revenue
Upfront License Fee
Research and development services
Details
Date
License and Collaboration Revenue
Upfront License Fee
Research and development services
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
86.10 M USD
75.50 M USD
1.71 M USD
Jan 1, 2020
0.00 USD
0.00 USD
754,000.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
1.48 M USD
Jan 1, 2022
0.00 USD
0.00 USD
1.68 M USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Agenus Revenue by Segment (3/4)

  • 3 Years

  • 5 Years

  • Max

License and collaboration milestones
Non-cash royalty revenue
License and Collaboration Revenue
Non cash royalty revenue related to the sale of future royalties
Other services
Recognition of Deferred Research and Development Revenue
License Fee Revenue
Research and development services
Manufacturing services
Other
Clinical Product Revenue
Recognition of Deferred Grant Revenue
Details
Date
License and collaboration milestones
Non-cash royalty revenue
License and Collaboration Revenue
Non cash royalty revenue related to the sale of future royalties
Other services
Recognition of Deferred Research and Development Revenue
License Fee Revenue
Research and development services
Manufacturing services
Other
Clinical Product Revenue
Recognition of Deferred Grant Revenue
Jan 1, 2018
0.00 USD
0.00 USD
23.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
4.15 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
30.42 M USD
0.00 USD
22.64 M USD
0.00 USD
0.00 USD
3.34 M USD
0.00 USD
0.00 USD
1.34 M USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
47.55 M USD
0.00 USD
12.30 M USD
22.86 M USD
0.00 USD
0.00 USD
4.62 M USD
0.00 USD
91,000.00 USD
Jan 1, 2021
220.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
22.36 M USD
0.00 USD
0.00 USD
0.00 USD
6.70 M USD
587,000.00 USD
184,000.00 USD
Jan 1, 2022
0.00 USD
45.29 M USD
0.00 USD
0.00 USD
10.51 M USD
9.54 M USD
5.00 M USD
0.00 USD
0.00 USD
0.00 USD
762,000.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
100.98 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.00 M USD
482,000.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
108.59 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.04 M USD
334,000.00 USD
0.00 USD

Agenus Revenue by Segment (4/4)

  • 3 Years

  • 5 Years

  • Max

License and collaboration milestones
Recognition of deferred revenue
Research and Development Manufacturing Services
Details
Date
License and collaboration milestones
Recognition of deferred revenue
Research and Development Manufacturing Services
Jan 1, 2018
14.00 M USD
1.33 M USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
291,000.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
106,000.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Agenus Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
Rest of world member
International
Europe
Details
Date
United States
Rest of world member
International
Europe
Jan 1, 2017
38.88 M USD
0.00 USD
0.00 USD
3.99 M USD
Jan 1, 2018
32.78 M USD
0.00 USD
0.00 USD
4.00 M USD
Jan 1, 2019
149.36 M USD
0.00 USD
0.00 USD
690,000.00 USD
Jan 1, 2020
83.55 M USD
4.62 M USD
4.62 M USD
0.00 USD
Jan 1, 2021
288.96 M USD
6.70 M USD
6.70 M USD
0.00 USD
Jan 1, 2022
87.51 M USD
0.00 USD
10.51 M USD
0.00 USD
Jan 1, 2024
101.46 M USD
0.00 USD
2.00 M USD
0.00 USD
Jan 1, 2025
113.16 M USD
0.00 USD
1.04 M USD
0.00 USD

Agenus Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Agenus historical P/E ratio, EBIT multiple, and P/S ratio

Agenus annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Agenus shares outstanding

The number of shares of Agenus was 35.32 M in 2025. This indicates how many shares Agenus is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
12.34 M Stocks
Jan 1, 2022
14.82 M Stocks
Jan 1, 2023
19.72 M Stocks
Jan 1, 2024
22.51 M Stocks
Jan 1, 2025
35.32 M Stocks
Jan 1, 2026 (e)
35.32 M Stocks
Jan 1, 2027 (e)
35.32 M Stocks
Jan 1, 2028 (e)
35.32 M Stocks

Agenus stock splits

In Agenus's history, there have been no stock splits.

Current Agenus forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
77.78 % (7)
Hold
22.22 % (2)
Sell
0.00 % (0)
12M Price Target
8.16
Last Price
7.97
Currency
USD
12M Return Potential
2.38 %
LTM Return
0 %

Agenus Analyst Rating Actions

DateFirmActionRatingReliability
7/13/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
9/10/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
8/28/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
6/4/2025
HC Wainwright & Co.
HC Wainwright & Co.
UpgradeNeutralBuy
6/4/2025
H.C. Wainwright
H.C. Wainwright
UpgradeNeutralBuy
6/4/2025
Baird
Baird
MaintainedNeutral
5/13/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral
5/13/2025
Baird
Baird
MaintainedNeutral
4/30/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral
3/18/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Agenus Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/20260.05USD-34.68 MUSD-2026 Q2
5/11/20262.14USD-132.09 MUSD-2026 Q1
3/9/2026-1.06USD-28.22 MUSD-2025 Q4
11/12/2024-2.38USD-34.15 MUSD-2024 Q3
5/7/2024-0.15USD--USD-2024 Q1
3/12/2024-0.05USD-48.00 MUSD-2023 Q4
11/6/2023-0.19USD--USD-2023 Q3
8/7/2023-0.19USD--USD-2023 Q2
5/8/2023-0.20USD--USD-2023 Q1
2/27/2023-0.18USD-27.30 MUSD-2022 Q4
...

EESG©

Eulerpool ESG Scorecard© for the Agenus stock

36/100
15
Environment
65
Social
29
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Agenus shareholder structure

% Name
11.96634%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.61532%
Armen (Garo H.)
Armen (Garo H.)
0.18271%
Key Client Fiduciary Advisors, LLC
Key Client Fiduciary Advisors, LLC
0.10282%
Harrison (Thomas L)
Harrison (Thomas L)
0.09383%
Vanguard Personalized Indexing Management, LLC
Vanguard Personalized Indexing Management, LLC
0.06210%
Values First Advisors, Inc.
Values First Advisors, Inc.

Agenus Beneficial Ownership Filings (SEC 13D/G)

Free Float
89.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
79.80%
Agenus Inc. (“Agenus”)
Agenus Inc. (“Agenus”)
SEC ↗
9.99%
n
n
SEC ↗
9.90%
RA Capital Management, L.P.
RA Capital Management, L.P.
SEC ↗
8.80%
Invus Public Equities, L.P.
Invus Public Equities, L.P.
SEC ↗
8.24%
STATE STREET CORPORATION
STATE STREET CORPORATION
SEC ↗
7.40%
Incyte Corporation
Incyte Corporation
SEC ↗
7.30%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
6.87%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
6.80%
2
2
SEC ↗
6.74%
SSGA FUNDS MANAGEMENT, INC.
SSGA FUNDS MANAGEMENT, INC.
SEC ↗

Agenus Executives and Management Board

9 members · avg. age 66 · 33 % women

GA

Dr. Garo Armen (72)

Chairman of the Board, Chief Executive Officer, Co-Founder · since 1994

3.72 M USD

Management

SO

Dr. Steven O'Day (64)

Chief Medical Officer

968,491.00 USD
CK

Ms. Christine Klaskin (59)

Vice President - Finance

483,477.00 USD
RG

Mr. Richard Goldberg

Chief Development Officer

Board of Directors

JB

Dr. Jennifer Buell (51)

Director · since 2018

7.42 M USD
BC

Mr. Brian Corvese (67)

Independent Director

490,308.00 USD
TW

Mr. Timothy Wright (67)

Lead Independent Director

232,883.00 USD
SH

Ms. Susan Hirsch (72)

Independent Director

138,950.00 USD
TH

Mr. Thomas Harrison (77)

Independent Director

64,677.00 USD

Agenus Supply Chain

Agenus Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
Targovax
Supplier·Customer·Biotechnology·NO
-0.09
0.83
0.32
0.66
0.92
0.49
2
UroGen Pharma
Supplier·Customer·Biotechnology·US
0.38
0.76
0.78
0.74
0.90
0.43
3
Betta Pharmaceuticals A
Supplier·Customer·Pharmaceuticals·CN
-0.06
-0.73
0.90
0.82
0.80
0.38
4
Gilead Sciences
Supplier·Customer·Biotechnology·US
-0.18
0.10
-0.38
0.52
0.57
0.38
5
Viatris
Supplier·Customer·Pharmaceuticals·US
-0.17
-0.58
-0.33
0.38
0.57
0.31
#NameTrend
1
Ginkgo Bioworks A
Supplier·Customer·Chemicals·US
0.43
0.90
0.65
0.77
0.72
2
GlaxoSmithKline
Supplier·Customer·Pharmaceuticals·GB
0.08
0.57
-0.84
-0.75
-0.87
-0.42
3
Bristol-Myers Squibb
Supplier·Customer·Pharmaceuticals·US
0.09
-0.37
-0.79
-0.80
-0.41
-0.32
4
Merck & Co
Supplier·Customer·Pharmaceuticals·US
-0.45
-0.64
-0.93
-0.84
-0.54
-0.31
5
Incyte
Supplier·Customer·Biotechnology·US
0.19
0.59
-0.03
-0.32
0.08
0.02

Frequently asked questions about Agenus

Analysts currently set an average price target of 12.58 USD for the Agenus stock (median: 8.16 USD), implying +57.8 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Agenus stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Agenus to generate revenue of 136.40 M USD and earnings per share of 0.40 USD.

Converted at the current exchange rate, the Agenus share trades at 6.90 EUR (7.97 USD).

The Agenus share (AGEN) is listed on 5 stock exchanges, including: NASDAQ (AGEN), Frankfurt (AJ81.F), München (AJ81.MU), Düsseldorf (AJ81.DU), SIX (Zürich) (AJ81.SW).

No history available for Agenus.

The expected revenue of Agenus is 136.40 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Agenus is 14.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Agenus is currently 19.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Agenus stock.

The price-to-sales ratio (P/S) of Agenus is currently 2.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Agenus stock.

The Eulerpool Quality Score for Agenus is 5/10.

The ISIN of Agenus is US00847G8042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Agenus is A1JLKZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Agenus is AGEN. The ticker symbol is used to trade Agenus shares on the stock exchange.

Agenus paid dividends every year for the past 0 years.

Agenus is assigned to the 'Health' sector.

The dividends of Agenus are distributed in USD.

All fundamentals and in-depth analysis of Agenus

Our stock analysis for Agenus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.